Contraline

Join us in welcoming Robert S. Goldman to the Contraline team! 👏

We are so excited to share that Contraline's first in-human trial shows safety with 12-month efficacy signals of the ADAM™ male contraceptive! Read more about it here: https://lnkd.in/gZ8KhMhi

Contraceptives should fit seamlessly into our lives. Don't you think?

"DNA Diagnostics Centre’s (DDC) at-home test will provide ADAM implant participants with accessible monitoring of sperm presence."

Today marks the 2 year anniversary of the overturn of Roe v. Wade. Following this ruling, research into male contraceptives has gained momentum. At the American Urological Association 2024 Annual Meeting, Dr. Stephanie T. Page highlighted new developments in male contraception. The urgency for these options is emphasized by the significant impact of unplanned pregnancies and the recent restrictions on abortion access in the US. Studies show growing interest from men in new contraceptive methods, with over 40% willing to use them within a year. Ongoing clinical trials are exploring both hormonal and non-hormonal options, promising a future with more balanced responsibilities in reproductive health. At Contraline, we are extremely proud to contribute to transforming the future of birth control options for men and applaud all the other innovators in this space who share our goal! Together, we can make a significant impact for men and women globally. 👏 🌎

"SpermCheck Vasectomy® will be utilized by patients implanted with ADAM to monitor the effectiveness of the male contraceptive in real-time. By offering a user-friendly and accessible solution for monitoring sperm presence, SpermCheck Vasectomy® enhances the convenience and reliability of ADAM as a male contraceptive option." Kevin Eisenfrats, co-founder & CEO of Contraline, remarked, “We are excited to integrate SpermCheck Vasectomy® into the trial. It’s a natural fit to combine an at-home diagnostic like SpermCheck Vasectomy® with a male contraceptive like ADAM because it will offer patients the ability to know whether ADAM is working from the privacy of their own home. We are excited to be collaborating with DNA Diagnostics Center to make this happen.”

Thank you CvilleBioHub and InBio for hosting Senator Mark Warner for a riveting discussion with biotech leaders in Charlottesville. Sen. Warner is dedicated to making Virginia a leader in the biotech industry. Contraline CEO, Kevin Eisenfrats, asked Sen. Warner, how male contraception could play a role in the current political climate. Sen. Warner expressed his enthusiasm and support for novel male contraceptives, stating, “I could see male contraception having bi-partisan support.”

Happy 10 year anniversary to our colleagues at the Male Contraceptive Initiative! In its 10-year history, MCI has become the biggest non-government funder in the male contraception space, providing financial support for 26 male contraceptive programs and 77 researchers. We thank MCI for supporting Contraline since the early days - first with a development grant and then a large program-related investment to support our First-in-Human trial. We look forward to a continued partnership with MCI as our two organizations work towards bringing new male contraceptives to the world in the coming years. Heather Vahdat, Logan Nickels, PhD, Kevin Shane, David Sokal, Beverly Tucker, Aaron Hamlin, Mitch Eddy, Deb Levine, Ted Benson, John De Caro

Last week, our CEO Kevin Eisenfrats and CTO Yelena Tropsha, PhD attended and presented at the 4th International Congress on Male Contraception (ICMC) at Rockefeller University in New York. The conference showcased that the field has advanced significantly with three novel male contraceptive methods now in the clinic. Contraline’s presentation discussed the journey of developing our vas-occlusive implant, ADAM, from concept to human trials. We celebrate all of the researchers who attended ICMC and choose to work on male contraception every day; together, we are on the brink of a cultural shift in shared reproductive responsibility.

Earlier this year, we conducted a survey to assess men's interest in male contraception, and within just 48 hours, we received over 1,000 responses! We were encouraged to find that 87.2% of respondents rated their desire to try male birth control as a 5 on a scale of 1 to 5, with 5 being the highest level of interest. (Read the full report here: https://lnkd.in/dEqM_Xhz) While the Dobbs decision may have brought the topic of reproductive health to the forefront of many peoples’ minds, the trend of men wanting to take more responsibility for family planning started well before 2022. This graph below specifically shows interest post Roe. v Wade: